Results 191 to 200 of about 33,034 (254)

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration

open access: yesArthritis &Rheumatology, EarlyView.
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis   +22 more
wiley   +1 more source

Risk of Retinal Vein Occlusion in Patients With Vitamin B<sub>12</sub> Deficiency and Hyperhomocysteinemia: A Propensity-Matched Cohort Study Using TriNetX. [PDF]

open access: yesJ Vitreoretin Dis
Shmushkevich SB   +10 more
europepmc   +1 more source

Higher Complement C4 Gene Copy Number Constitutes a Shared Genetic Risk Factor for Giant Cell Arteritis and IgA Vasculitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Low copy number (CN) of complement C4 isoforms and high CN of retroviral HERV‐K elements are known risk factors for many immune‐mediated inflammatory diseases (IMIDs), often showing sex‐biased effects. Here, we assessed whether CN variation within the C4 gene contributes to giant cell arteritis (GCA) and IgA vasculitis (IgAV), two complex ...
Laura Martínez‐Gutiérrez   +295 more
wiley   +1 more source

Hereditary red cell defects as an underrecognized cause of neonatal jaundice. [PDF]

open access: yesJ Perinatol
Komvilaisak P   +9 more
europepmc   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia   +16 more
wiley   +1 more source

Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+‐year results from a multicenter, open‐label study

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients 2–17 years with active pcJIA and inadequate response ...
Hermine I Brunner   +28 more
wiley   +1 more source

Optimizing Oligonucleotide Therapeutics: A Model-Informed Drug Development Perspective. [PDF]

open access: yesClin Transl Sci
Yuan Y   +7 more
europepmc   +1 more source

Student‐identified barriers to histology learning and the perceived value of coloring as a multimodal educational strategy

open access: yesAnatomical Sciences Education, EarlyView.
Abstract Histology is a visually complex and cognitively demanding subject often perceived as abstract, memorization‐heavy, and disconnected from clinical practice. Despite its foundational importance, histology is frequently under‐emphasized relative to gross anatomy and lacks interactive, multimodal resources tailored to its unique challenges.
Anika Knowles   +2 more
wiley   +1 more source

A 53-week, open-label phase IIIb study of velaglucerase alfa in Chinese patients with type 1 Gaucher disease: Safety, efficacy, and pharmacokinetics. [PDF]

open access: yesMol Genet Metab Rep
Zhang L   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy